8103 related articles for article (PubMed ID: 16078447)
1. [Correlation between functional capability and phenotypic characteristics of peripheral blood lymphocytes in patients with malignant melanoma].
Konjević G; Jović V; Radomirović V; Spuzić I
Glas Srp Akad Nauka Med; 2002; (47):121-36. PubMed ID: 16078447
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic implications of the kinetics of immunomodulation during single or combined treatment of melanoma patients with dacarbazine and interferon-alpha.
Konjević G; Jović V; Radulović S; Jelić S; Dzodić R; Spuzić I
Neoplasma; 2001; 48(3):175-81. PubMed ID: 11583285
[TBL] [Abstract][Full Text] [Related]
3. CD69 on CD56+ NK cells and response to chemoimmunotherapy in metastatic melanoma.
Konjević G; Jović V; Vuletić A; Radulović S; Jelić S; Spuzić I
Eur J Clin Invest; 2007 Nov; 37(11):887-96. PubMed ID: 17973783
[TBL] [Abstract][Full Text] [Related]
4. Changes in immunological parameters after combination adjuvant therapy with intravenous DTIC, ACNU, and VCR, and local injection of IFN-beta (DAV + IFN-beta therapy) into malignant melanoma.
Umeda T; Aoki K; Yokoyama A; Ohara H; Hayashi O; Tanaka K; Nishioka K
J Dermatol; 1998 Sep; 25(9):569-72. PubMed ID: 9798342
[TBL] [Abstract][Full Text] [Related]
5. The expression of cytotoxic mediators is altered in mononuclear cells of patients with melanoma and increased by interferon-alpha treatment.
Guillot B; Portalès P; Thanh AD; Merlet S; Dereure O; Clot J; Corbeau P
Br J Dermatol; 2005 Apr; 152(4):690-6. PubMed ID: 15840100
[TBL] [Abstract][Full Text] [Related]
6. IL-2-mediated augmentation of NK-cell activity and activation antigen expression on NK- and T-cell subsets in patients with metastatic melanoma treated with interferon-alpha and DTIC.
Konjević G; Jović V; Jurisić V; Radulović S; Jelić S; Spuzić I
Clin Exp Metastasis; 2003; 20(7):647-55. PubMed ID: 14669796
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
8. A pilot study of intralymphatic interleukin-2. I. Cytotoxic and surface marker changes of peripheral blood lymphocytes.
Shau H; Isacescu V; Ibayashi Y; Tokuda Y; Golub SH; Fahey JL; Sarna GP
J Biol Response Mod; 1990 Feb; 9(1):71-80. PubMed ID: 2319261
[TBL] [Abstract][Full Text] [Related]
9. Comparative study on the effects of recombinant alpha-2 interferon on immune function in patients with disseminated melanoma.
Hersey P; Coates A; Rallings M; Hall C; MacDonald M; Spurling A; Edwards A; McCarthy WH; Milton GW
J Biol Response Mod; 1986 Jun; 5(3):236-49. PubMed ID: 3487622
[TBL] [Abstract][Full Text] [Related]
10. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.
Varker KA; Kondadasula SV; Go MR; Lesinski GB; Ghosh-Berkebile R; Lehman A; Monk JP; Olencki T; Kendra K; Carson WE
Clin Cancer Res; 2006 Oct; 12(19):5850-8. PubMed ID: 17020993
[TBL] [Abstract][Full Text] [Related]
11. Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients.
Molenkamp BG; Sluijter BJ; van Leeuwen PA; Santegoets SJ; Meijer S; Wijnands PG; Haanen JB; van den Eertwegh AJ; Scheper RJ; de Gruijl TD
Clin Cancer Res; 2008 Jul; 14(14):4532-42. PubMed ID: 18628468
[TBL] [Abstract][Full Text] [Related]
12. Local immunotherapy with interferon-alpha in metastatic pleural and peritoneal effusions: correlation with immunologic parameters.
Stathopoulos GP; Baxevanis CN; Papadopoulos NG; Zarkadis IK; Papacostas P; Michailakis E; Tsiatas ML; Papamichail M
Anticancer Res; 1996; 16(6B):3855-60. PubMed ID: 9042270
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
Daponte A; Ascierto PA; Gravina A; Melucci MT; Palmieri G; Comella P; Cellerino R; DeLena M; Marini G; Comella G;
Cancer; 2000 Dec; 89(12):2630-6. PubMed ID: 11135225
[TBL] [Abstract][Full Text] [Related]
14. DTIC vs. IFN-alpha plus DTIC in the treatment of patients with metastatic malignant melanoma.
Rudolf Z; Strojan P
Neoplasma; 1996; 43(2):93-7. PubMed ID: 8843969
[TBL] [Abstract][Full Text] [Related]
15. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Iversen TZ
Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
[TBL] [Abstract][Full Text] [Related]
16. [Interferon therapy effects on activation of T-lymphocytes in patients with systemic lupus erythematosus].
Stanislav ML; Balabanova RM; Nikonova MF; Litvina MM; Iarilin AA
Ter Arkh; 2000; 72(5):44-9. PubMed ID: 11109620
[TBL] [Abstract][Full Text] [Related]
17. Natural killer receptors on CD8 T cells and natural killer cells from different HLA-C phenotypes in melanoma patients.
Campillo JA; Martínez-Escribano JA; Moya-Quiles MR; Marín LA; Muro M; Guerra N; Parrado A; Campos M; Frías JF; Minguela A; García-Alonso AM; Alvarez-López MR
Clin Cancer Res; 2006 Aug; 12(16):4822-31. PubMed ID: 16914567
[TBL] [Abstract][Full Text] [Related]
18. Expression of HLA-A2 antigen in human melanoma cell lines and its role in T-cell recognition.
Pandolfi F; Boyle LA; Trentin L; Kurnick JT; Isselbacher KJ; Gattoni-Celli S
Cancer Res; 1991 Jun; 51(12):3164-70. PubMed ID: 1904004
[TBL] [Abstract][Full Text] [Related]
19. [Chemoimmunotherapy with dacarbazine and aranose combined with interferon-alpha in disseminated cutaneous melanoma].
Gershanovich ML; Akimov MA
Vopr Onkol; 2004; 50(2):179-83. PubMed ID: 15176220
[TBL] [Abstract][Full Text] [Related]
20. Perilesional treatment of metastatic melanoma with interferon-beta.
Fujimura T; Okuyama R; Ohtani T; Ito Y; Haga T; Hashimoto A; Aiba S
Clin Exp Dermatol; 2009 Oct; 34(7):793-9. PubMed ID: 19438554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]